We've engaged 50,000+ patients and enrolled 1,000+ participants across oncology and hematology studies. Now we're bringing that infrastructure to Chronic Lymphocytic Leukemia (CLL).

Leapcure recruits patients with complex, layered eligibility through named blood cancer advocacy relationships, caregiver-informed outreach, and cross-specialty referral coordination, then pre-screens every referral so sites get patients ready to enroll.

Talk to our CLL teamSee how it works →
1,000+
Patients enrolled
across oncology and hematology studies
27
Advocate partnerships activated
for a Phase 1 hematologic gene therapy program
20+
Patients queued for site screening
within 4 months on the same program
$35
Blended referral acquisition cost
using behavioral pre-screening data

Understanding Chronic Lymphocytic Leukemia as a Clinical Trial Indication

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, a slow-growing blood cancer in which the bone marrow overproduces abnormal B lymphocytes. It is largely a disease of older adults, with a median age at diagnosis in the early 70s, and many patients are diagnosed incidentally from a routine blood count while feeling well. Because early-stage CLL is often monitored rather than treated, the population is defined less by acute symptoms than by long-term surveillance, immune compromise, and the accumulation of other age-related conditions.

For sponsors, that patient profile is exactly what makes CLL recruitment hard. Eligibility criteria are complex and layered: prior lines of therapy, cytogenetic and molecular markers such as del(17p) and TP53 or IGHV mutation status, absolute lymphocyte counts, and organ function all narrow the pool, and most patients do not track these markers themselves. CLL patients are frequently immunocompromised and prone to infection, are managed across oncology, immunology, and infectious disease specialists, and often rely on a family caregiver to navigate decisions. Trials also run long, so retention and trust matter as much as first contact.

Leapcure brings deep oncology and hematology recruitment infrastructure to CLL: 50,000+ patients engaged and 1,000+ enrolled across studies spanning metastatic breast cancer, myelodysplastic syndrome, bladder cancer, and peripheral T-cell lymphoma, named blood cancer advocacy relationships including Blood Cancer Alliance and Blood Cancer UK, and direct experience screening for complex hematologic eligibility. On a Phase 1 hematologic gene therapy program, we activated 27 advocate partnerships, queued 20+ patients for site-level screening within 4 months, doubled site consenting activity, and achieved a $35 blended referral acquisition cost using behavioral pre-screening data. That is the skill set CLL recruitment demands.

The Challenge

CLL trial recruitment is not a reach problem. It is a complexity problem: an older, immunocompromised population with layered eligibility, cross-specialty care, and long timelines.

An older, immunocompromised population is harder to reach and enroll

Most CLL patients are diagnosed in their 70s, are prone to infection, and weigh trial participation against real risks to a fragile immune system. Standard digital campaigns that work for younger, healthier indications surface interest that does not convert, because the barriers here are clinical and personal, not awareness alone.

Across oncology and hematology programs, Leapcure has engaged 50,000+ patients and enrolled 1,000+, including older and immunocompromised populations that require education-forward, high-touch outreach rather than volume advertising.

Layered eligibility criteria shrink the pool and slow screening

CLL protocols filter on prior therapy, cytogenetic and molecular markers such as del(17p), TP53, and IGHV status, lymphocyte counts, and organ function. Patients rarely track these markers, so untargeted referrals fail eligibility late and waste coordinator time. Screening for CLL means screening for that full profile before a patient reaches a site.

On a Phase 1 hematologic gene therapy program, Leapcure queued 20+ patients for site-level screening within 4 months and doubled site consenting activity by pre-screening against complex hematologic eligibility before referral.

Care is split across multiple specialists, and caregivers drive decisions

CLL patients are managed across oncology, immunology, and infectious disease, and the referral path to a trial is rarely linear. Family caregivers often carry the research and the decision. Recruitment that ignores the caregiver, or that cannot coordinate across specialties, loses eligible patients in the handoffs.

Leapcure's caregiver-informed outreach and cross-specialty referral coordination are built into how we engage hematology and rare disease patients, the same coordination CLL enrollment depends on.

Long study timelines put retention and trust at risk

CLL trials can run for years, and enrollment risk does not end at consent. Patients who do not feel supported drop out, and sites that lose momentum stall. Sustained engagement, not a one-time referral push, is what keeps a long CLL study on track.

Leapcure's behavioral pre-screening and Patient Success support achieved a $35 blended referral acquisition cost on a hematologic program while keeping patients engaged through site-level screening, evidence of durable engagement rather than a single burst of leads.

Three steps. One strategy built for your CLL trial.

Leapcure applies its oncology and blood cancer infrastructure to your protocol, your sites, and your eligibility criteria, then coordinates the specialty handoffs that CLL recruitment requires.

1

Activate advocacy and digital across our oncology and blood cancer network

We launch outreach through named blood cancer advocacy relationships, including Blood Cancer Alliance and Blood Cancer UK, inside a broader oncology advocacy network spanning metastatic breast cancer, myelodysplastic syndrome, bladder cancer, and peripheral T-cell lymphoma communities, paired with precision digital targeted to your eligibility criteria and site locations.

2

Engage patients and caregivers with education-forward, high-touch outreach

CLL decisions are rarely made alone. We engage patients and their caregivers early, explain what a marker-driven eligibility check involves, and support the immune-compromise and infection concerns that shape whether a patient will consider a trial. Every referral is pre-screened against protocol eligibility before it reaches a site.

3

Coordinate referral pathways across oncology, immunology, and infectious disease

Because CLL care is split across specialties, we coordinate the referral path rather than leaving it to chance, aligning outreach with how patients actually move between their oncologist and the trial site. We track referral quality and site capacity continuously and rebalance channels as sites engage.

Oncology-wide scale plus a proven hematology playbook, ready for CLL.

Challenge Context

Experience

Oncology and hematology recruitment across metastatic breast cancer, myelodysplastic syndrome, bladder cancer, peripheral T-cell lymphoma, and genetic and gene therapy studies.

Sponsor

Leading Hematology Sponsor, Phase 1 hematologic gene therapy program (no study named)

Challenge

Complex, layered hematologic eligibility, an immunocompromised population managed across multiple specialists, caregiver-driven decisions, and the need to queue screen-ready patients quickly without a same-indication case study to lean on.

Channels Deployed

Named blood cancer advocacy relationships, education-forward patient and caregiver outreach, precision digital, cross-specialty referral coordination, and behavioral pre-screening.

Results & Metrics

Oncology and Hematology Scale

50,000+ patients engaged and 1,000+ participants enrolled across oncology and hematology studies.

Advocacy Activation

27 advocate partnerships activated for a Phase 1 hematologic gene therapy program.

Speed to Screening

20+ patients queued for site-level screening within 4 months, doubling site consenting activity.

Referral Efficiency

$35 blended referral acquisition cost, achieved using behavioral data applied during pre-screening.

Sponsor Attribution

Leading Hematology Sponsor, Phase 1 hematologic gene therapy

Four capabilities. Built in oncology and hematology. Ready for CLL.

Leapcure reaches and qualifies CLL patients through named blood cancer advocacy, caregiver-informed patient support, cross-specialty referral coordination, and answer-engine visibility delivered to your trial.

Blood Cancer Advocacy Network

  • •Named blood cancer advocacy relationships, including Blood Cancer Alliance and Blood Cancer UK, sit inside a broader oncology advocacy network.
  • •That broader network spans metastatic breast cancer, myelodysplastic syndrome, bladder cancer, and peripheral T-cell lymphoma communities, so outreach reaches patients through sources they already trust.
  • •Content is co-developed with partners rather than pushed as an unsolicited ad, which is what earns attention from an older, cautious population.

Caregiver-Informed Patient Support

  • •A high-touch Patient Success team engages both the patient and the family caregiver who often drives the decision.
  • •We address immune compromise, infection risk, and the realities of a long study from first contact, so referrals arrive informed and prepared.
  • •This support model is why our referrals convert rather than stall at the site.

Cross-Specialty Referral Coordination

  • •CLL patients are managed across oncology, immunology, and infectious disease, so we coordinate the referral path across specialties rather than relying on a single point of contact.
  • •Every referral is pre-screened against layered eligibility, including marker and prior-therapy requirements, before it reaches a coordinator.
  • •The result is screen-ready patients and less wasted site time.

Answer-Engine and AI-Search Visibility

  • •CLL patients and caregivers increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
  • •We do this with crawlable, factually rich content, cited sources, and presence in the advocacy and community sources AI engines actually cite, not schema tricks or content written for machines.
  • •This puts your study where high-intent patients and caregivers are already looking.

Named relationships in blood cancer, inside a broader oncology network

Leapcure's blood cancer advocacy relationships are named and active. The wider oncology network is counted, not name-dropped, so every relationship on this page is real.

Blood Cancer Alliance

Named blood cancer advocacy relationship anchoring trust for hematologic outreach

Blood Cancer UK

Leading UK blood cancer organization extending reach into the patient community

Broader oncology advocacy network

Advocacy relationships across metastatic breast cancer, myelodysplastic syndrome, bladder cancer, and peripheral T-cell lymphoma communities, counted rather than individually named

Living with CLL? A clinical trial may be an option.

If you or someone you care for is living with chronic lymphocytic leukemia, a clinical trial may offer access to investigational treatments that are not yet widely available. We know CLL often means watchful waiting, infection worries, and appointments across several specialists. Leapcure's team offers step-by-step support, answers your questions, and includes your family or caregivers wherever that helps.

See if a CLL trial may be right for you
Leapcure kangaroo mascot

Leapcure has engaged 50,000+ patients and enrolled 1,000+ across oncology and hematology studies, with named blood cancer advocacy relationships and proven experience screening for complex hematologic eligibility. We deploy advocacy, precision digital, caregiver-informed outreach, and cross-specialty referral coordination adapted to your CLL protocol. Talk to our CLL team about your active or upcoming study.

Talk to our CLL team